Udit Singhal, MD
Manage Your Profile
About
Dr. Singhal is a board-certified urologic oncologist who specializes in the management of patients with kidney, prostate, bladder, testis, upper tract urothelial, and penile cancers. He completed his residency training in urology at the University of Michigan in Ann Arbor, MI, and his research fellowship training in translational science at the University of Michigan. He then completed his clinical urological oncology fellowship at the Mayo Clinic in Rochester, MN. He performs advanced open, endoscopic, laparoscopic, and robotic surgery.
Dr. Singhal’s research interests include the development and implementation of novel, precision-based diagnostics and therapeutics in all genitourinary malignancies. He has a special interest in the integration of genomics into biomarker-driven clinical trials in oncology, with the goal of optimally defining the clinical application of these tests. He has received grant funding for his research from the National Institutes of Health, National Cancer Institute, Prostate Cancer Foundation, Urology Care Foundation, University of Michigan, and industry partners. He has additionally received top honors and awards for his research from the Prostate Cancer Foundation, Urology Care Foundation, American Society of Clinical Oncology, and American Association for Cancer Research. He also serves as peer reviewer for many leading academic journals and is a member of numerous professional societies, including the American Urological Association, Society of Urologic Oncology, SWOG Cancer Research Network, SUO Clinical Trials Consortium, and the American Society of Clinical Oncology.
Qualifications
-
Urologic OncologyMayo Clinic, Rochester, USA
2023 - 2024
Postdoctoral Fellowship
-
Translational Research - Urologic OncologyUniversity of Michigan, Ann Arbor, USA
2021 - 2023
Postdoctoral Research
-
UrologyUniversity of Michigan, Ann Arbor, USA
2016 - 2021
Residency
-
Chief ResidentUniversity of Michigan, Ann Arbor, USA
2020 - 2021
Chief Resident
-
MDWright State University Boonshoft School of Medicine, USA
2011 - 2016
-
BSThe Ohio State University, Columbus, United States
2006 - 2010
Center Memberships
-
Center MemberAI and Digital Health Innovation
Recent Publications
-
Roberson DS, Psutka SP, Meeks JJ, Clinton TN, Pessoa RR, Joyce DD, Singhal U, Bivalacqua TJ, Britton CJ, Kirschenbaum M, Torgerson H, Wan V, Yim K, Wang S, Lyon TD, Tyson MD, Pierorazio PM, Luckenbaugh AN, Li R, Boorjian SA, Khanna A. Journal of Urology, 2026 Apr 30; 215 (5S): e745Journal ArticleIP36-22 PERIOPERATIVE AND ONCOLOGIC OUTCOMES OF CONSOLIDATIVE SURGERY FOR ADVANCED UROTHELIAL CARCINOMA FOLLOWING INDUCTION ENFORTUMAB VEDOTIN AND PEMBROLIZUMAB: A MULTICENTER EXPERIENCE
DOI:10.1097/01.ju.0001191488.74766.a1.22 -
Nakhjiri M, Chaudhury S, Kriko Y, Orabi M, Bao L, Horn M, Avery R, Grajqevci A, Chang A, Odell D, Singhal U, Reddy RM, Borza T, Hughes T, Sabel M, Dossett L, Piche J, Aibinder W, Merajver S, Merrill N. Cancer Research, 2026 Apr 5; 86 (7_Supplement): 6961 - 6961.Journal ArticleAbstract 6961: Patient matched organoid-immune co-culture model as a predictive platform for immunotherapy response in precision oncology
DOI:10.1158/1538-7445.am2026-6961 -
Singhal U, Jiang R, Proudfoot JA, Chase E, Suresh K, Davicioni E, Borza T, Zelefsky MJ, Davis BJ, Stish BJ, Karnes RJ, Freedland SJ, Terris MK, Aronson WJ, Cooperberg MR, Moraes FY, Berlin A, Deville C, Zaorsky NG, Roy S, Jia AY, Shoag JE, Jackson WC, Spratt DE, Schipper M, Morgan TM, Dess RT. Prostate Cancer Prostatic Dis, 2025 Dec 9;Journal ArticleCharacterizing population-wide genomic risk distribution for development of a novel clinical-genomic risk system for prognostication in patients with clinically localized prostate cancer.
DOI:10.1038/s41391-025-01062-8 PMID: 41366130 -
Singhal U. 2026 Mar 3;Presentation"Metastatic RCC with bulky primary: Navigating the balance between local and systematic therapy."
Featured News & Stories